Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Lipella Pharmaceuticals's pretax income for the
three
months ended in Sep. 2025 was $-1.25 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Sep. 2025 was $-5.33 Mil.
Lipella Pharmaceuticals's pretax margin was %.
During the past 5 years, Lipella Pharmaceuticals's highest Pretax Margin was -6.44%. The lowest was -1411.96%. And the median was -935.82%.
During the past 5 years, Lipella Pharmaceuticals's highest Pretax Margin was -6.44%. The lowest was -1411.96%. And the median was -935.82%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipella Pharmaceuticals Pre-Tax Income Related Terms
Lipella Pharmaceuticals Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LIPO vs WINT, ITRMF, IOBTQ: Pre-Tax Income Comparison
For the Biotechnology subindustry, Lipella Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipella Pharmaceuticals Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Lipella Pharmaceuticals's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipella Pharmaceuticals (LIPO) has a Pre-Tax Income of $-5.33 Mil as of Sep. 2025. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Lipella Pharmaceuticals and its competitors.
Is Lipella Pharmaceuticals' Pre-Tax Income too high?
Lipella Pharmaceuticals' current Pre-Tax Income is $-5.33 Mil.
How does Lipella Pharmaceuticals' Pre-Tax Income compare to WINT and ITRMF?
Lipella Pharmaceuticals' Pre-Tax Income of $-5.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Lipella Pharmaceuticals and its competitors. Lipella Pharmaceuticals's current Pre-Tax Income is $-5.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.87, compared to a current price of $0.00 — trading 100% below its estimated fair value. The current Pre-Tax Income is $-5.33 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current Pre-Tax Income is $-5.33 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIPO has been successfully added to your 
